1
|
Jalilian AR, Shahi A, Swainson IP, Nakamura H, Venkatesh M, Osso JA. Potential Theranostic Boron Neutron Capture Therapy Agents as Multimodal Radiopharmaceuticals. Cancer Biother Radiopharm 2022; 37:342-354. [DOI: 10.1089/cbr.2021.0276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Amir R. Jalilian
- Nuclear Sciences and Applications Department, International Atomic Energy Agency, Vienna, Austria
| | - Arman Shahi
- Faculty of Science, McMaster University, Hamilton, Canada
| | - Ian P. Swainson
- Nuclear Sciences and Applications Department, International Atomic Energy Agency, Vienna, Austria
| | - Hiroyuki Nakamura
- Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, Midori-ku, Yokohama, Japan
| | - Meera Venkatesh
- Nuclear Sciences and Applications Department, International Atomic Energy Agency, Vienna, Austria
| | - Joao A. Osso
- Nuclear Sciences and Applications Department, International Atomic Energy Agency, Vienna, Austria
| |
Collapse
|
2
|
Gruzdev DA, Levit GL, Krasnov VP, Charushin VN. Carborane-containing amino acids and peptides: Synthesis, properties and applications. Coord Chem Rev 2021. [DOI: 10.1016/j.ccr.2020.213753] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
3
|
Hoppenz P, Els-Heindl S, Beck-Sickinger AG. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front Chem 2020; 8:571. [PMID: 32733853 PMCID: PMC7359416 DOI: 10.3389/fchem.2020.00571] [Citation(s) in RCA: 132] [Impact Index Per Article: 33.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Accepted: 06/03/2020] [Indexed: 12/15/2022] Open
Abstract
Cancer became recently the leading cause of death in industrialized countries. Even though standard treatments achieve significant effects in growth inhibition and tumor elimination, they cause severe side effects as most of the applied drugs exhibit only minor selectivity for the malignant tissue. Hence, specific addressing of tumor cells without affecting healthy tissue is currently a major desire in cancer therapy. Cell surface receptors, which bind peptides are frequently overexpressed on cancer cells and can therefore be considered as promising targets for selective tumor therapy. In this review, the benefits of peptides as tumor homing agents are presented and an overview of the most commonly addressed peptide receptors is given. A special focus was set on the bombesin receptor family and the neuropeptide Y receptor family. In the second part, the specific requirements of peptide-drug conjugates (PDC) and intelligent linker structures as an essential component of PDC are outlined. Furthermore, different drug cargos are presented including classical and recent toxic agents as well as radionuclides for diagnostic and therapeutic approaches. In the last part, boron neutron capture therapy as advanced targeted cancer therapy is introduced and past and recent developments are reviewed.
Collapse
Affiliation(s)
- Paul Hoppenz
- Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany
| | - Sylvia Els-Heindl
- Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Leipzig, Germany
| | | |
Collapse
|
4
|
Worm DJ, Els‐Heindl S, Beck‐Sickinger AG. Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates. Pept Sci (Hoboken) 2020. [DOI: 10.1002/pep2.24171] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Dennis J. Worm
- Faculty of Life Sciences, Institute of BiochemistryLeipzig University Leipzig Germany
| | - Sylvia Els‐Heindl
- Faculty of Life Sciences, Institute of BiochemistryLeipzig University Leipzig Germany
| | | |
Collapse
|
5
|
Hoppenz P, Els-Heindl S, Kellert M, Kuhnert R, Saretz S, Lerchen HG, Köbberling J, Riedl B, Hey-Hawkins E, Beck-Sickinger AG. A Selective Carborane-Functionalized Gastrin-Releasing Peptide Receptor Agonist as Boron Delivery Agent for Boron Neutron Capture Therapy. J Org Chem 2019; 85:1446-1457. [PMID: 31813224 DOI: 10.1021/acs.joc.9b02406] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Boron neutron capture therapy (BNCT) allows the selective elimination of malignant tumor cells without affecting healthy tissue. Although this binary radiotherapy approach has been known for decades, BNCT failed to reach the daily clinics to date. One of the reasons is the lack of selective boron delivery agents. Using boron loaded peptide conjugates, which address G protein-coupled receptors overexpressed on tumor cells allow the intracellular accumulation of boron. The gastrin-releasing peptide receptor (GRPR) is a well-known target in cancer diagnosis and can potentially be used for BNCT. Here, we present the successful introduction of multiple bis-deoxygalactosyl-carborane building blocks to the GRPR-selective ligand [d-Phe6, β-Ala11, Ala13, Nle14]Bn(6-14) (sBB2L) generating peptide conjugates with up to 80 boron atoms per molecule. Receptor activation was retained, metabolic stability was increased, and uptake into PC3 cells was proven without showing any intrinsic cytotoxicity. Furthermore, undesired uptake into liver cells was suppressed by using l-deoxygalactosyl modified carborane building blocks. Due to its high boron loading and excellent GRPR selectivity, this conjugate can be considered as a promising boron delivery agent for BNCT.
Collapse
Affiliation(s)
- Paul Hoppenz
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| | - Sylvia Els-Heindl
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| | - Martin Kellert
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Robert Kuhnert
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Stefan Saretz
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | | | | | - Bernd Riedl
- Bayer AG , Aprather Weg 18A , Wuppertal , Germany
| | - Evamarie Hey-Hawkins
- Institute of Inorganic Chemistry , Leipzig University , Johannisallee 29 , 04103 Leipzig , Germany
| | - Annette G Beck-Sickinger
- Institute of Biochemistry, Faculty of Life Sciences , Leipzig University , Brüderstrasse 34 , 04103 Leipzig , Germany
| |
Collapse
|
6
|
Worm DJ, Hoppenz P, Els-Heindl S, Kellert M, Kuhnert R, Saretz S, Köbberling J, Riedl B, Hey-Hawkins E, Beck-Sickinger AG. Selective Neuropeptide Y Conjugates with Maximized Carborane Loading as Promising Boron Delivery Agents for Boron Neutron Capture Therapy. J Med Chem 2019; 63:2358-2371. [PMID: 31589041 DOI: 10.1021/acs.jmedchem.9b01136] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
G-protein-coupled receptors like the human Y1 receptor (hY1R) are promising targets in cancer therapy due to their high overexpression on cancer cells and their ability to internalize together with the bound ligand. This mechanism was exploited to shuttle boron atoms into cancer cells for the application of boron neutron capture therapy (BNCT), a noninvasive approach to eliminate cancer cells. A maximized number of carboranes was introduced to the hY1R-preferring ligand [F7,P34]-NPY by solid phase peptide synthesis. Branched conjugates loaded with up to 80 boron atoms per peptide molecule exhibited a maintained receptor activation profile, and the selective uptake into hY1R-expressing cells was demonstrated by internalization studies. In order to ensure appropriate solubility in aqueous solution, we proved the need for eight hydroxyl groups per carborane. Thus, we suggest the utilization of bis-deoxygalactosyl-carborane building blocks in solid phase peptide synthesis to produce selective boron delivery agents for BNCT.
Collapse
Affiliation(s)
- Dennis J Worm
- Institute of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany
| | - Paul Hoppenz
- Institute of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany
| | - Sylvia Els-Heindl
- Institute of Biochemistry, Leipzig University, Brüderstrasse 34, 04103 Leipzig, Germany
| | - Martin Kellert
- Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany
| | - Robert Kuhnert
- Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany
| | - Stefan Saretz
- Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany
| | | | - Bernd Riedl
- Bayer AG, Aprather Weg 18A, 42113 Wuppertal, Germany
| | - Evamarie Hey-Hawkins
- Institute of Inorganic Chemistry, Leipzig University, Johannisallee 29, 04103 Leipzig, Germany
| | | |
Collapse
|
7
|
Yinghuai Z, Lin X, Xie H, Li J, Hosmane NS, Zhang Y. The Current Status and Perspectives of Delivery Strategy for Boron-based Drugs. Curr Med Chem 2018; 26:5019-5035. [PMID: 30182851 DOI: 10.2174/0929867325666180904105212] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2018] [Revised: 07/26/2018] [Accepted: 07/27/2018] [Indexed: 12/27/2022]
Abstract
Boron-containing compounds are essential micronutrients for animals and plants despite their low-level natural occurrence. They can strengthen the cell walls of the plants and they play important role in supporting bone health. However, surprisingly, boron-containing compounds are seldom found in pharmaceutical drugs. In fact, there are no inherent disadvantages reported so far in terms of the incorporation of boron into medicines. Indeed, drugs based on boron-containing compounds, such as tavaborole (marked name Kerydin) and bortezomib (trade name Velcade) have been investigated and they are used in clinical treatment. In addition, following the advanced development of boron neutron capture therapy and a new emerging proton boron fusion therapy, more boron-containing medicinals are to be expected. This review discusses the current status and perspectives of delivery strategy for boron-containing drugs.
Collapse
Affiliation(s)
- Zhu Yinghuai
- School of Pharmacy, Macau University of Science and Technology, Avenida Wai Long, Taipa 999078, Macau. Macao
| | - Xinglong Lin
- New Drug Research Institute, HEC Pharma Group, Dongguan 523871. China
| | - Hongming Xie
- New Drug Research Institute, HEC Pharma Group, Dongguan 523871. China
| | - Jianlin Li
- HEC Research and Development Center, Dongguan 523871. China
| | - Narayan S Hosmane
- Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, Illinois 60115-2862. United States
| | - Yingjun Zhang
- New Drug Research Institute, HEC Pharma Group, Dongguan 523871. China
| |
Collapse
|
8
|
Worm DJ, Els-Heindl S, Kellert M, Kuhnert R, Saretz S, Koebberling J, Riedl B, Hey-Hawkins E, Beck-Sickinger AG. A stable meta-carborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor. J Pept Sci 2018; 24:e3119. [PMID: 30168238 DOI: 10.1002/psc.3119] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 07/18/2018] [Accepted: 07/19/2018] [Indexed: 12/26/2022]
Abstract
Boron neutron capture therapy (BNCT) is a binary cancer therapy, which combines the biochemical targeting of a boron-containing drug with the regional localization of radiation treatment. Although the concept of BNCT has been known for decades, the selective delivery of boron into tumor cells remains challenging. G protein-coupled receptors that are overexpressed on cancer cells in combination with peptidic ligands can be potentially used as shuttle system for a tumor-directed boron uptake. In this study, we present the generation of short, boron-rich peptide conjugates that target the ghrelin receptor. Expression of the ghrelin receptor on various cancer cells makes it a viable target for BNCT. We designed a novel hexapeptide super-agonist that was modified with different specifically synthesized carborane monoclusters and tested for ghrelin receptor activation. A meta-carborane building block with a mercaptoacetic acid linker was found to be optimal for peptide modification, owing to its chemical stability and a suitable activation efficacy of the conjugate. The versatility of this carborane for the development of peptidic boron delivery agents was further demonstrated by the generation of highly potent, boron-loaded conjugates using the backbone of the known ghrelin receptor ligands growth hormone releasing peptide 6 and Ipamorelin.
Collapse
Affiliation(s)
- Dennis J Worm
- Faculty of Life Sciences, Institute of Biochemistry, Universität Leipzig, Brüderstrasse 34, 04103, Leipzig, Germany
| | - Sylvia Els-Heindl
- Faculty of Life Sciences, Institute of Biochemistry, Universität Leipzig, Brüderstrasse 34, 04103, Leipzig, Germany
| | - Martin Kellert
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, 04103, Leipzig, Germany
| | - Robert Kuhnert
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, 04103, Leipzig, Germany
| | - Stefan Saretz
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, 04103, Leipzig, Germany
| | | | - Bernd Riedl
- Bayer AG, Aprather Weg 18A, 42113, Wuppertal, Germany
| | - Evamarie Hey-Hawkins
- Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, 04103, Leipzig, Germany
| | - Annette G Beck-Sickinger
- Faculty of Life Sciences, Institute of Biochemistry, Universität Leipzig, Brüderstrasse 34, 04103, Leipzig, Germany
| |
Collapse
|
9
|
Tanaka T, Sawamoto Y, Aoki S. Concise and Versatile Synthesis of Sulfoquinovosyl Acyl Glycerol Derivatives for Biological Applications. Chem Pharm Bull (Tokyo) 2017; 65:566-572. [PMID: 28566649 DOI: 10.1248/cpb.c17-00135] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Sulfoquinovosyl acylpropanediol (SQAP), a chemically modified analogue of sulfoquinovosyl acylglycerol (SQAG) that occurs in sea algae, has been reported to show a variety of biological activities, including accumulation in tumor cells and the inhibition of tumor cell growth. We report herein on a new concise and versatile synthesis of SQAP itself and derivatives bearing iodoaryl groups and boronclusters. This method should be useful for the design and synthesis of SQAG/SQAP derivatives for diagnosis and the treatment of cancer and related diseases.
Collapse
Affiliation(s)
- Tomohiro Tanaka
- Faculty of Pharmaceutical Sciences, Tokyo University of Science
| | | | - Shin Aoki
- Faculty of Pharmaceutical Sciences, Tokyo University of Science.,Division of Medical-Science-Engineering Cooperation, Research Institute for Science and Technology, Tokyo University of Science.,Imaging Frontier Center, Resarch Institute for Science and Technology, Tokyo University of Science
| |
Collapse
|
10
|
A convenient route towards deoxygalactosyl-functionalised ortho -carbaborane: Synthesis of a building block for peptide conjugation. J Organomet Chem 2015. [DOI: 10.1016/j.jorganchem.2015.08.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
11
|
Frank R, Ahrens V, Boehnke S, Hofmann S, Kellert M, Saretz S, Pandey S, Sárosi M, Bartók Á, Beck-Sickinger AG, Hey-Hawkins E. Carbaboranes – more than just phenyl mimetics. PURE APPL CHEM 2015. [DOI: 10.1515/pac-2014-1006] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AbstractDicarba-closo-dodecaboranes(12) (C2B10H12, carbaboranes) are highly hydrophobic and stable icosahedral carbon-containing boron clusters. The cage framework of these clusters can be modified with a variety of substituents, both at the carbon and at the boron atoms. Substituted carbaboranes are of interest in medicine as boron neutron capture therapy (BNCT) agents or as pharmacophores. High and selective accumulation in tumour cells is an important requirement for a BNCT agent and is achieved by incorporating boron-rich, water-soluble carbaborane derivatives into breast tumour-selective modified neuropeptide Y, [F7, P34]-NPY. Preliminary studies showed that the receptor binding affinity and signal transduction of the boron-modified peptides were very well retained. Use of carbaboranes as pharmacophores was shown by replacement of Bpa32 (Bpa=benzoylphenylalanine) in the reduced-size NPY analogue [Pro30, Nle31, Bpa32, Leu34]-NPY 28–36 by ortho-carbaboranyl propanoic acid. The inclusion of the carbaborane derivative resulted in a short NPY agonist with an interesting hY2R/hY4R preference. This might be a promising approach in the field of anti-obesity drug development.
Collapse
Affiliation(s)
- René Frank
- 1Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, D-04103 Leipzig, Germany
| | - Verena Ahrens
- 2Institute of Biochemistry, Universität Leipzig, Brüderstraße 34, D-04103 Leipzig, Germany
| | - Solveig Boehnke
- 1Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, D-04103 Leipzig, Germany
| | - Sven Hofmann
- 2Institute of Biochemistry, Universität Leipzig, Brüderstraße 34, D-04103 Leipzig, Germany
| | - Martin Kellert
- 1Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, D-04103 Leipzig, Germany
| | - Stefan Saretz
- 1Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, D-04103 Leipzig, Germany
| | - Souvik Pandey
- 1Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, D-04103 Leipzig, Germany
| | - Menyhárt Sárosi
- 1Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, D-04103 Leipzig, Germany
| | - Ágota Bartók
- 1Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, D-04103 Leipzig, Germany
| | | | - Evamarie Hey-Hawkins
- 1Institute of Inorganic Chemistry, Universität Leipzig, Johannisallee 29, D-04103 Leipzig, Germany
| |
Collapse
|
12
|
Hofmann S, Frank R, Hey-Hawkins E, Beck-Sickinger AG, Schmidt P. Manipulating Y receptor subtype activation of short neuropeptide Y analogs by introducing carbaboranes. Neuropeptides 2013; 47:59-66. [PMID: 23352609 DOI: 10.1016/j.npep.2012.12.001] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2012] [Revised: 11/27/2012] [Accepted: 12/07/2012] [Indexed: 12/23/2022]
Abstract
Short selective neuropeptide Y (NPY) analogs are highly attractive because of their facile synthesis. Based on the reduced-size NPY analog [Pro(30), Nle(31), Bpa(32), Leu(34)]NPY 28-36 position 32 was identified as a key position to alter the preferential activation pattern of the human neuropeptide Y receptors (hYRs). By replacing benzoylphenylalanine (Bpa) by a biphenylalanine (Bip) the photostability was first improved while the biological activity was maintained. SAR-studies showed that both aromatic rings have a high influence on the preferential hYR subtype activation. Interestingly, replacement of Bpa(32) by a strongly hydrophobic moiety changed the hYR subtype preference of the analog. Whereas the parent compound is able to activate the human neuropeptide Y1 receptor (hY1R) subtype, the introduction of an N(ε)-ortho-carbaboranyl propionic acid modified lysine resulted in a loss of activity at the hY1R but in an increased activity at both the hY2R and the hY4R. However, subsequent receptor internalization studies with this novel analog revealed that receptor internalization can neither be triggered at the hY2R nor at the hY4R suggesting a biased ligand. Surprisingly, investigations by (1)H NMR spectroscopy revealed structural changes in the side chains of residues Pro(30) and Leu(34) which nicely correlates with the shift from hY1R/hY4R to hY2R/hY4R activation preference. Thus, position 32 has been identified to switch the bioactive conformation and subsequently influences receptor subtype activation behavior.
Collapse
Affiliation(s)
- S Hofmann
- Universität Leipzig, Institute of Biochemistry, Leipzig, Germany
| | | | | | | | | |
Collapse
|
13
|
Ahrens VM, Frank R, Stadlbauer S, Beck-Sickinger AG, Hey-Hawkins E. Incorporation of ortho-Carbaboranyl-Nε-Modified l-Lysine into Neuropeptide Y Receptor Y1- and Y2-Selective Analogues. J Med Chem 2011; 54:2368-77. [DOI: 10.1021/jm101514m] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Verena M. Ahrens
- Universität Leipzig, Institute of Biochemistry, Brüderstraße 34, 04103 Leipzig
| | - René Frank
- Universität Leipzig, Institute of Inorganic Chemistry, Johannisallee 29, 04103 Leipzig
| | - Sven Stadlbauer
- Universität Leipzig, Institute of Inorganic Chemistry, Johannisallee 29, 04103 Leipzig
| | | | - Evamarie Hey-Hawkins
- Universität Leipzig, Institute of Inorganic Chemistry, Johannisallee 29, 04103 Leipzig
| |
Collapse
|
14
|
Sivaev IB, Bregadze VV. Polyhedral Boranes for Medical Applications: Current Status and Perspectives. Eur J Inorg Chem 2009. [DOI: 10.1002/ejic.200900003] [Citation(s) in RCA: 287] [Impact Index Per Article: 19.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- Igor B. Sivaev
- A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., Moscow 119991, Russia, Fax: +7‐499‐1355085
| | - Vladimir V. Bregadze
- A. N. Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, 28 Vavilov Str., Moscow 119991, Russia, Fax: +7‐499‐1355085
| |
Collapse
|
15
|
Kabalka GW, Wu Z, Yao ML. Synthesis of a series of boronated unnatural cyclic amino acids as potential boron neutron capture therapy agents. Appl Organomet Chem 2008. [DOI: 10.1002/aoc.1435] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
16
|
Betzel T, Heß T, Waser B, Reubi JC, Roesch F. closo-Borane Conjugated Regulatory Peptides Retain High Biological Affinity: Synthesis of closo-Borane Conjugated Tyr3-Octreotate Derivatives for BNCT. Bioconjug Chem 2008; 19:1796-802. [DOI: 10.1021/bc800101h] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Thomas Betzel
- Institute of Nuclear Chemistry, University of Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany
| | - Tobias Heß
- Institute of Nuclear Chemistry, University of Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany
| | - Beatrice Waser
- Institute of Nuclear Chemistry, University of Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany
| | - Jean-C. Reubi
- Institute of Nuclear Chemistry, University of Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany
| | - Frank Roesch
- Institute of Nuclear Chemistry, University of Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany
| |
Collapse
|
17
|
Schirrmacher R, Bradtmöller G, Schirrmacher E, Thews O, Tillmanns J, Siessmeier T, Buchholz HG, Bartenstein P, Wängler B, Niemeyer CM, Jurkschat K. 18F-labeling of peptides by means of an organosilicon-based fluoride acceptor. Angew Chem Int Ed Engl 2007; 45:6047-50. [PMID: 16888726 DOI: 10.1002/anie.200600795] [Citation(s) in RCA: 172] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Ralf Schirrmacher
- Klinik und Poliklinik für Nuklearmedizin, Johannes Gutenberg Universität Mainz, 55131 Mainz, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Schirrmacher R, Bradtmöller G, Schirrmacher E, Thews O, Tillmanns J, Siessmeier T, Buchholz HG, Bartenstein P, Wängler B, Niemeyer CM, Jurkschat K. 18F-Markierung von Peptiden mithilfe eines Organosilicium-Fluoridacceptors. Angew Chem Int Ed Engl 2006. [DOI: 10.1002/ange.200600795] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
19
|
Kabalka GW, Yao ML. Synthesis of 1-Amino-3-[(dihydroxyboryl)methyl]- cyclobutanecarboxylic Acid as a Potential Therapy Agent. J Org Chem 2004; 69:8280-6. [PMID: 15549798 DOI: 10.1021/jo048824c] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A novel boronated aminocyclobutanecarboxylic acid (1) was synthesized for potential use in boron neutron capture therapy. Starting from the readily available 3-(bromomethyl)cyclobutanone ketal (4), several synthetic routes to 1 were evaluated. After several unsuccessful attempts with traditional synthetic methods, a novel synthetic strategy to generate the new boronated cyclic amino acid was developed. The tolerance of the hydantoin group to the selenoxide elimination reaction conditions in the preparation of alkenyl compound 7 proved to be the key step in the new strategy.
Collapse
Affiliation(s)
- George W Kabalka
- Department of Chemistry, The University of Tennessee, Knoxville, Tennessee 37996-1600, USA.
| | | |
Collapse
|
20
|
|